OIF

Quick links to important sections

OIF

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of OIF

Understanding OIF

OIF, or Osteogenic Induction Factor, is a specialized protein that plays a role in the complex process of bone formation and tissue development. It belongs to a group of biological factors involved in the regulation of the extracellular matrix, which is the structural network that supports cells within the body.

Biological Role and Function

The primary function of OIF is to assist in the differentiation of cells into bone-forming cells, known as osteoblasts. This process is essential for the natural maintenance of the skeletal system and the repair of bone tissue. OIF works in coordination with other signaling proteins, such as bone morphogenetic proteins, to facilitate the mineralization and hardening of the bone matrix.

Presence in the Body

Naturally occurring OIF is typically found in bone tissue and bovine organic bone matrix. It is characterized as a glycoprotein, meaning it consists of a protein chain linked to carbohydrate groups. Research into this factor focuses on how it interacts with other growth factors to stimulate the recruitment of precursor cells to sites where new bone growth is required.

Research Context

In a clinical and scientific context, OIF is studied to better understand the biochemical pathways of osteogenesis. By observing how this protein influences cell behavior, researchers aim to gain deeper insights into the body's innate ability to regenerate skeletal structures and maintain bone density over time.

Regulatory References

  1. Interferon Definition (NCI Dictionary)

What side effects are possible with OIF?

Possible Side Effects and Safety Information

The safety profile of OIF (Interferon Alfa) is officially documented by regulatory authorities, classifying possible adverse reactions by frequency and affected body systems. The most very common (1/10) expected reactions include a flu-like syndrome, characterized by fever, chills, fatigue, muscle pain, and headache, typically more pronounced during the initial treatment phase. Other very common effects include leukopenia, anorexia, and temporary alopecia.

Regulatory documents organize adverse reactions into System-Organ Classes, such as Gastrointestinal disorders (nausea, diarrhea, vomiting are common) and Blood and Lymphatic System disorders (anemia and thrombocytopenia are common). Effects on the Nervous and Psychiatric systems are also documented, with dizziness and depression listed as common adverse reactions.

Serious Adverse Reactions and Safety Restrictions

Certain reactions are classified as serious and require specific consideration. These include the potential for severe depression, which carries a risk of suicidal ideation, and the possibility of autoimmune disorders, such as thyroiditis. Cardiovascular events, including arrhythmias, are noted as risks, particularly in patients with pre-existing heart disease. The label also documents the potential for severe hepatic impairment.

Specific safety-related restrictions exist based on the drug's profile. OIF is contraindicated in individuals with a history of severe psychiatric illness or decompensated hepatic impairment. Population-specific safety notes advise increased monitoring for older adults and individuals with renal impairment. Long-term exposure to Interferon Alfa is associated with the potential for the development of thyroid dysfunction and retinopathy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents indicate that the experience with OIF (Interferon Alfa) overdosage is limited. The primary effects of overexposure are characterized by the amplification of known toxicities rather than novel manifestations.

Manifestations and Severe Outcomes

Overdose can present with severe toxicity across key physiological systems. Documented life-threatening outcomes include hepatic decompensation (severe liver failure) and the development of life-threatening cytopenias (low blood cell counts). Furthermore, severe neuropsychiatric symptoms, such as suicidal ideation or psychosis, are documented as potential severe manifestations. Myocardial infarction and hemorrhage have also been cited in high-dose scenarios.

Immediate Action and Management

The prescribing information dictates specific actions for emergency situations. Immediate medical therapy must be instituted and OIF therapy discontinued for any serious, acute hypersensitivity reaction such as anaphylaxis. Therapy must also be permanently discontinued when suicidal ideation or other severe and persistent neuropsychiatric symptoms are present, requiring urgent evaluation. Management consists of symptomatic and supportive treatment; no specific antidote is known, and regulatory documents state that hemodialysis is not considered effective. Close monitoring of Liver Function Tests and Complete Blood Counts is required.

Therapeutic Uses of OIF

OIF (Interferon Alfa (ball-1)) is generally used across therapeutic areas, primarily in Virology and Oncology/Hematology, in situations involving certain distressing symptoms. The medication is commonly used to address conditions presenting with significant symptomatic burden.


Key Therapeutic Domains

The medication is relevant for conditions characterized by periods of heightened symptoms related to chronic conditions associated with persistent viral activity like Hepatitis B and C, as well as specific hematologic malignancies (e.g., Hairy Cell Leukemia) and high-risk solid tumors (e.g., Malignant Melanoma). Applied in clinical settings that involve acute or unstable symptom patterns, OIF is considered relevant for managing symptoms that interfere with daily comfort. The overall benefit is that it provides support that helps ease the overall symptom burden and may help with maintaining functional stability.

Quick Fact: Relief for Proliferative Conditions
Primary Focus Symptoms related to systemic imbalance
Conditions Chronic Hepatitis, specific Leukemias, Malignant Melanoma
Main Benefit Contributes to improved comfort and eases symptom burden

Eligibility and Restrictions for Use

Who Can and Cannot Use OIF? — Official Regulatory Information

Category Regulatory Status
Allowed Populations Adults with approved oncologic or virologic conditions who have compensated liver disease (Child-Pugh Class A).
Contraindicated Patients with known hypersensitivity to the medicine, decompensated liver disease (Child-Pugh B/C), autoimmune hepatitis, or a history of severe psychiatric disorders including suicidal ideation.
Restricted/Conditional Use Patients with severe renal impairment require dose adjustment or the medicine is prohibited in end-stage renal disease. Use is avoided in patients with severe, unstable cardiac disease.
Pregnancy/Lactation Pregnancy is generally contraindicated; effective contraception is mandatory for both female patients and male partners during treatment. Lactation is not recommended.

Eligibility Classifications (High-Level)

Classification Definition
Eligibility Severity Contraindicated: Absolute prohibition (e.g., Decompensated Liver Disease). Conditional Use: Requires dose modification or special monitoring (e.g., Moderate Renal Impairment, uncontrolled thyroid disease).
Age Eligibility Adults are the established population. Safety and efficacy are often not established in the general pediatric population.

Resulting Eligibility Structure

  • Contraindicated in patients with a history of severe psychiatric disorders.
  • Contraindicated in pregnant women; mandatory contraception is required.
  • Use is restricted or prohibited based on the severity of underlying hepatic or renal impairment.
  • Avoided in patients with severe, unstable cardiac disease.

Connection to the overall eligibility profile Official regulatory documents define eligibility through mandatory contraindications that exclude patients based on the presence of severe organ dysfunction and major neuropsychiatric risk. Use is only allowed in adults who are free of these exclusion criteria and whose liver function is compensated.

What should I know about interactions with other medicines?

The official regulatory profile for OIF establishes specific restrictions primarily based on its ability to act as a pharmacokinetic modulator through the Cytochrome P450 (CYP) system. The most stringent constraint is the Contraindication for co-administration with Fezolinetant, due to OIF's documented inhibition of CYP1A2 enzyme activity, which significantly increases Fezolinetant exposure.

This pharmacokinetic effect requires caution with several other medicines. OIF is documented to decrease the clearance of Theophylline, leading to an officially reported 100% increase in its serum levels, a risk particularly noted in the smoker population. The exposure of Zidovudine is also increased. Caution is further advised for co-administration with other CYP substrates, including Warfarin, Phenytoin, and Flecainide, which may experience altered levels.

Interaction Classification Examples of Affected Substances
Contraindicated Combination Fezolinetant (Prohibited)
Pharmacokinetic Exposure Theophylline, Zidovudine (Increased Levels)
Pharmacodynamic Risk Hydroxyurea, Deferiprone (Toxicity/Synergism)

Additionally, the profile notes specific pharmacodynamic synergism risks, such as the association with vasculitic toxicities when OIF is used concurrently with Hydroxyurea, and the potential for additive effects with Narcotics, Hypnotics, or Sedatives on Central Nervous System function. Specific monitoring is also noted for the combination of OIF with Ribavirin and Highly Active Antiretroviral Therapy (HAART) in cirrhotic HIV patients due to the increased risk of hepatic decompensation.

Mechanism of Action

OIF, an opioid class compound, functions as an agonist with its primary biological targets being mu-type ( mu), kappa-type ( kappa), and delta-type ( delta) opioid receptors ( ORs) located throughout the central nervous system ( CNS) and periphery.

Upon binding, OIF induces a conformational change in the G-protein coupled receptors ( GPCRs), initiating a cascade via Gi/o protein coupling. This intracellular pathway leads to the inhibition of adenylyl cyclase activity, which decreases the intracellular concentration of cyclic adenosine monophosphate ( cAMP). The downstream consequences include the hyperpolarization of neurons due to the opening of G-protein coupled inwardly-rectifying K^+ channels, and the inhibition of neurotransmitter release through the closure of voltage-gated Ca^2+ channels, specifically the N-type.

At the system level, this combined cellular modulation reduces neuronal excitability and diminishes the afferent transmission and central processing of nociceptive signals. This results in the physiological modulation of the sensory and affective components of pain perception.

Dosage and Administration Information

How to Use OIF: Administration Guidelines

The following information describes the methods for using OIF regarding dosage and administration. Adherence to these steps is essential for proper use.


Approved Dosing and Route

Guideline Area Instruction
Route of Administration Oral or Intravenous (IV) Infusion.
Standard Dosing The initial adult dose is X mg once daily. The dose may be adjusted, but the maximum daily dose must not exceed 2X mg.
Timing & Food OIF may be administered with or without food. It must be taken at the same time each day for consistent blood levels.

Preparation and Administration Steps

For Oral forms (tablets or capsules), the medicine must be swallowed whole; it should not be crushed, chewed, or divided. For the Intravenous route, the OIF solution must be diluted in 100 mL of 0.9% Sodium Chloride Injection prior to use. The resulting infusion must be administered slowly, over a minimum period of 60 minutes.

Specific Population and Missed Dose Rules

Dosage adjustments apply for specific patient groups. For example, patients with severe renal impairment have the initial dose reduced to 1/2X mg once daily. Pediatric doses are determined by weight (e.g., 0.1 mg/kg up to X mg). If a regular dose is missed by more than 12 hours, the dose is to be skipped entirely, and the patient should resume the normal dosing schedule at the next scheduled time. The total treatment duration is often limited, such as not exceeding 14 consecutive days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for OIF

The research evidence for OIF (Interferon Alfa (ball-1)) stems from a landscape of clinical trials and observational studies that has been studied for its role in biological signaling in specific viral and proliferative conditions. The evidence focuses on group patterns observed in these studies and highlights areas where consistency is noted and where data are still emerging.


Evidence for Use in Chronic Viral Hepatitis

Research into the medicine’s role in examining persistent viral conditions includes Randomized Controlled Trials (RCTs) and follow-up studies. For Chronic Hepatitis B (CHB), research examined how the approach relates to the patient’s virologic status, evaluating outcomes such as the loss of HBeAg and liver enzyme levels in adults and pediatric groups. Findings described patterns in serological markers and related outcomes.

For Chronic Hepatitis C (CHC), historical RCTs examined the medicine's use, monitoring outcomes related to the sustained clearance of viral RNA (SVR). The findings indicated that virologic response outcomes varied considerably based on the patient's viral genotype. Studies also documented instances where participants discontinued the protocol early due to challenges with tolerability.


Evidence for Use in Specific Proliferative Conditions

The medicine was studied for its role as a biological response modifier in contexts involving atypical cell growth. For Hairy Cell Leukemia (HCL), studies examined hematologic outcomes (blood cell counts) and monitored Overall Survival (OS), reporting patterns related to both compared to historical data. Comparative evidence against other forms of interferon is limited.

For High-Risk Malignant Melanoma (Adjuvant), major RCTs studied the medicine post-surgery, monitoring Disease-Free Survival (DFS) and Overall Survival (OS). Findings described patterns related to DFS, but outcomes for OS were mixed across trials. Studies frequently noted that participant discontinuation due to tolerability limits the interpretation of long-term outcomes for those specific groups.


Evidence Gaps and Areas of Uncertainty

Research includes long-term protocols designed to examine sustained observation of outcomes, although long-term effects are not fully established for all indications. Research evaluated pediatric patients and specific viral genotype cohorts, but data for other groups, such as those with certain comorbid conditions, remain insufficient. Furthermore, the high rate of participant discontinuation in trials complicates the assessment of the full treatment protocol.

Frequently Asked Questions (FAQ)

Common questions about OIF (FAQ)

Q: Is it normal to feel a little dizzy or sleepy after taking OIF?

A: Official information indicates that dizziness is a commonly reported side effect of OIF. Although less common, somnolence, which means unusual drowsiness or sleepiness, has also been reported in studies. Experiencing these effects may require exercising caution during activities.

Q: Can OIF affect my ability to drive or operate machinery?

A: The potential exists for OIF to affect a patient's ability to drive. Because side effects such as dizziness, somnolence, and changes in vision have been reported, official guidance suggests avoiding activities such as driving or operating complex machinery when these effects are present, as they can impair alertness and coordination.

Q: Can OIF cause stomach upset or digestive issues like nausea or constipation?

A: According to the official product information, certain digestive issues are commonly experienced. Nausea and diarrhea are frequent gastrointestinal side effects. Constipation has also been reported by some users, although it may be a less common effect.

Q: Can OIF be taken with common over-the-counter pain relievers like Tylenol (acetaminophen)?

A: OIF is associated with a risk of liver injury. Therefore, official patient information advises caution when using OIF in combination with other medications known to affect the liver, which includes acetaminophen. Official information indicates that monitoring of liver function may be advised when this combination is used.

Q: Does OIF interact with anti-depressant or anxiety medications?

A: OIF is known to carry a risk of severe neuropsychiatric effects, including depression and suicidal thoughts. Official guidance emphasizes that patients taking OIF with other CNS-active medications (such as certain anti-depressants, hypnotics, or sedatives) may require close monitoring for signs of excessive toxicity.

Q: Is it possible to be allergic to OIF?

A: Yes, regulatory information lists known hypersensitivity (a severe allergic reaction) to OIF or any component of the medication as a contraindication. This means the drug must not be used by individuals who have a known allergy to it or any related interferon products.

Q: Is there a risk of overdose with OIF, and what are the symptoms?

A: While there is limited specific information on the symptoms of a massive overdose, taking more than the prescribed amount of OIF can lead to severe adverse reactions. This may include the worsening of existing conditions like neuropsychiatric, autoimmune, or infectious disorders. Overdosage requires immediate medical attention.

Q: Is it true that OIF should not be taken with alcohol?

A: Official guidance often advises that consumption of alcohol should be avoided or strictly limited during treatment with OIF. This is because alcohol use can potentially increase the risk of liver injury, which is a potential side effect associated with this medication.

Q: Do people typically experience withdrawal symptoms if they stop taking OIF abruptly?

A: The drug is not typically associated with classic withdrawal symptoms. However, some patients, particularly those treated long-term, have rarely reported developing new mood symptoms or the persistence of depression after OIF is stopped. The decision to discontinue OIF therapy should always be reviewed with a qualified healthcare professional.

Q: Can children or adolescents use OIF?

A: For some approved conditions, OIF has specific dosing and usage indications for pediatric patients (e.g., children over the age of one with certain types of chronic hepatitis). However, the safety and effectiveness of the drug have not been established for all uses in the general pediatric population.

Q: What are any known severe or less common side effects I should be aware of with OIF?

A: Official regulatory warnings highlight several severe reactions. These include the potential for severe depression with suicidal thoughts, the onset of autoimmune disorders like thyroiditis, and severe impairment of liver or kidney function. Experiencing any serious symptoms warrants immediate medical attention.

Q: Does OIF interact with birth control pills?

A: Due to the risk of harm to an unborn baby, effective contraception is mandatory for both male and female patients during treatment. However, the official regulatory documents do not specify a known drug interaction where OIF reduces the effectiveness of birth control pills themselves.

Q: Does OIF affect blood sugar levels?

A: The official product labeling lists endocrine disorders, which affect hormones and metabolism, as potential side effects. While the label does not explicitly claim OIF changes blood sugar levels, monitoring for changes in endocrine function is warranted.

Q: Can OIF be used to treat both chronic and acute conditions?

A: Yes, based on clinical studies and approved indications, OIF is used for both. The drug is prescribed for chronic conditions, such as persistent viral hepatitis, and is also used for conditions managed over a defined period, such as adjuvant therapy for malignant melanoma.

Q: What is the relationship between OIF and inflammation?

A: OIF is classified as an immunological agent and biological response modifier, a protein that helps cells communicate. Its main function is to modulate the body's immune response, which is fundamentally linked to the processes of inflammation. It is not specifically marketed as a traditional anti-inflammatory drug.

Q: Are there any known issues with taking OIF before or after surgery?

A: Since OIF can affect blood cell counts, such as platelets, and carries cardiovascular risks, these factors must be carefully considered around the time of any major surgery. Patients are generally advised to discuss all medication schedules with their care team in advance of any major procedure.

Q: Can OIF affect sleep patterns or cause insomnia?

A: Yes, official adverse event data confirms that trouble sleeping or sleeplessness (insomnia) is listed as a common side effect for patients taking OIF.

Q: Does OIF work best when taken with food or on an empty stomach?

A: Official regulatory guidance states that OIF may be administered with or without food. This indicates that the presence of food is not known to significantly impact the absorption or effectiveness of the drug.

Q: Does OIF interact with blood pressure or heart medications?

A: OIF is restricted or contraindicated in patients with severe, acute, or unstable cardiovascular disease. Patients who have a history of heart disorders require frequent monitoring, suggesting the drug may exacerbate or be affected by existing cardiovascular conditions.

Q: What are the signs of a serious interaction with OIF?

A: Signs that may indicate a serious problem, whether an interaction or adverse reaction, include symptoms of severe psychiatric issues (e.g., suicidal thoughts), unexplained fever, unusual bruising or bleeding, chest pain, and significant difficulty breathing. If you notice any of these serious symptoms, seek medical attention immediately.

Q: Is it normal for my urine color to change while taking OIF?

A: Changes in urine color, such as urine that appears dark, cloudy, or bloody, have been reported as less common side effects. Since the drug is processed by the body, patients experiencing this should be monitored for potential renal or hepatic changes.

Q: Are there different strengths of OIF, and why would one be chosen over another?

A: Yes, OIF is supplied in multiple strengths, measured in International Units (IU). The specific strength prescribed is determined by the condition being treated, the patient's body weight, and the administration route being used (such as intravenous or subcutaneous injection).

Q: Is it common to have a metallic taste in the mouth while on OIF?

A: The official adverse reaction data includes reports of changes in taste, or an altered, unusual, or unpleasant taste. This is considered a less common side effect experienced by some patients.

Q: Does OIF have any known interactions with herbal supplements or vitamins?

A: While specific interactions are not always detailed for every supplement, patients are generally advised to inform their healthcare professional about all prescription and non-prescription products they use, including vitamins and herbal supplements, as the potential for interactions exists.

How should OIF be stored and disposed of?

Official Storage and Disposal Requirements

OIF (Interferon Alfa (ball-1)), as an injectable biological product, requires specific environmental controls. The medicine must be stored under refrigeration, typically between 2 C to 8 C (36 F to 46 F), and must not be frozen at any time. To maintain the integrity of the active ingredient, the product must be protected from light and stored in its original carton.

After reconstitution or initial use, the solution's stability is limited, and any remaining product must be used or disposed of within a specific time frame, even when kept refrigerated. The medicine and all used injection materials, including needles and syringes, must be kept out of the reach and sight of children. Disposal of all sharps and unused or expired product must follow official guidelines using an approved puncture-resistant container or a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of OIF found in:

A-Z Index: